Real Endpoints Founder, Roger Longman, is looking forward to leading a robust discussion focused on solutions to creating access to cell and gene therapies — solutions that work for both payers and biopharma.

Taking place on the first day of ASCO, the 5th Annual Immuno-Oncology BD&L and Investment Forum is designed to bring together thought leaders from cancer research institutes, patient advocacy groups, pharma and biotech to facilitate partnering, funding and investment. We expect around 250 delegates and about 30 presentations by listed and private biotechnology companies seeking licensing & investment. Numerous networking opportunities available via an online one-to-one meeting system with dedicated meeting facilities to make the event more transactional.

PANEL DISCUSSION I: Impact of Pricing and Policy on the Next Decade of Therapeutic Innovation

Innovative and novel financing and reimbursement strategies may be needed to support sustainable patient access to these new treatments. During this session, managed care and provider strategies for addressing gene therapy will be explored.

The potential for gene therapy to transform the treatment of a wide variety of health conditions has important implications for many stakeholders. During this panel discussion, participants will have the opportunity to hone in on pressing issues raised throughout the conference and discuss these issues with a panel of experts with varying backgrounds, including both clinical and managed care perspectives.

Departure from traditional dosage-based models makes it difficult for therapy developers, payers, patients, and investors to plan for a new therapy’s rollout and breadth of patient access. This session will explore the early lessons from current value-based agreements to explain the payers’ expectations for future models of reimbursing treatments based on outcomes versus delivery.